(Q28743480)

English

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice

scientific article (publication date: 2011)

In more languages

Statements

scholarly article

0 references

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice (English)

0 references

author name string

Peter Joseph Jongen

1

0 references

Christian Sindic

2

0 references

Evert Sanders

3

0 references

Stanley Hawkins

4

0 references

Wim Linssen

5

0 references

Erik van Munster

6

0 references

Stephan Frequin

7

0 references

George Borm

8

0 references

language of work or name

0 references

publication date

2011

0 references

0 references

6

0 references

10

0 references

e26568

0 references

copyright license

Creative Commons Attribution 4.0 International

25 October 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

16 March 2017

Multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

7 April 2017

Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

3 June 2018

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3201962

27 November 2018

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting of safety data from randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability of symptom reports by healthy volunteers treated with placebo over several time periods

1 reference

https://pubmed.ncbi.nlm.nih.gov/22046309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0026568

0 references

2011PLoSO...626568J

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28743480&oldid=2175356557"